Nanotechnology systems for drug delivery, multi-modal targeting and imaging of tumors

Cancer is one of the leading causes of deaths (1.6 million deaths annually) in USA. Despite recent advances in chemotherapy, the survival rates in lung cancer patients are unsatisfactory due to limited efficiency of systemic or oral chemotherapy and associated side effects. Oral administration of anti-cancer agents presents a series of advantages for patients. However, most of these agents are hydrophobic and associated with low bioavailability. To overcome this issue we have designed: 1) a unique customized spray gun which allows simultaneously /pulsatile flow of two different liquid systems through single nozzle. This modification allowed us to formulate enteric coated SEDDS (E-SEDDS) of anticancer agents for oral delivery by using SEDDS as one liquid system and enteric coating solution as second liquid system. 2) Tumor homing nanoparticle of bio-imaging agents (D-Luciferin) will target tumor and enhance the time duration of imaging, which can be used for delivering therapeutics.

[1]  S. Safe,et al.  A new class of peroxisome proliferator-activated receptor γ (PPARγ) agonists that inhibit growth of breast cancer cells: 1,1-Bis(3′-indolyl)-1-(p-substituted phenyl)methanes , 2004, Molecular Cancer Therapeutics.

[2]  Michael J Sailor,et al.  Biomimetic amplification of nanoparticle homing to tumors , 2007, Proceedings of the National Academy of Sciences.

[3]  P. Nawroth,et al.  Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[4]  S. Baek,et al.  1,1-Bis(3′-indolyl)-1-(p-substitutedphenyl)methanes Are Peroxisome Proliferator-Activated Receptor γ Agonists but Decrease HCT-116 Colon Cancer Cell Survival through Receptor-Independent Activation of Early Growth Response-1 and Nonsteroidal Anti-Inflammatory Drug-Activated Gene-1 , 2005, Molecular Pharmacology.

[5]  M. Konopleva,et al.  A novel ring-substituted diindolylmethane,1,1-bis[3'-(5-methoxyindolyl)]-1-(p-t-butylphenyl) methane, inhibits extracellular signal-regulated kinase activation and induces apoptosis in acute myelogenous leukemia. , 2005, Cancer research.

[6]  Steven E Schild,et al.  Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. , 2008, Mayo Clinic proceedings.

[7]  Lisa Brannon-Peppas,et al.  Active targeting schemes for nanoparticle systems in cancer therapeutics. , 2008, Advanced drug delivery reviews.

[8]  E. Ruoslahti,et al.  Peptides selected for binding to clotted plasma accumulate in tumor stroma and wounds. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[9]  M. Abdelrahim,et al.  A new class of peroxisome proliferator-activated receptor gamma (PPARgamma) agonists that inhibit growth of breast cancer cells: 1,1-Bis(3'-indolyl)-1-(p-substituted phenyl)methanes. , 2004, Molecular Cancer Therapeutics.

[10]  S. Safe,et al.  Enhancement of Docetaxel Anticancer Activity by a Novel Diindolylmethane Compound in Human Non–Small Cell Lung Cancer , 2009, Clinical Cancer Research.

[11]  H. Dvorak,et al.  Regulation of extravascular coagulation by microvascular permeability. , 1985, Science.